Methyl-Synephrine HCL
Do not mistake this compound for pure synephrine! It is light years away, in terms of superiority. If synephrine worked for you, Methyl-Synephrine HCL will blow your mind! First, back to the basics. What is synephrine? Obtained from the citrus tree known as Citrus aurantium or Bitter Orange, synephrine is an active alkaloid with structural similarities to epinephrine and norepinephrine. Synephrine’s claimed thermogenic, lipolytic, and appetite suppression effects are derived from its alpha-adrenergic properties that provoke the activation of beta-3 receptors. The claim that synephrine’s beta-3-receptor binding triggers lipolysis at very high dosages appeared to based on Carpene et al (1999). Subsequent studies, e.g., Larsen et al (2002) and Bent et al (2004), however, demonstrated that beta-3-receptor agonists appeared to have dramatically less lipolytic action in human fat cells, compared to animal fat cells.
The picture, however, appears to change significantly with the use of a recently developed unique form of synephrine referred to as Methyl Synephrine. Using the methylated form of synephrine (derived by substituting or attaching a methyl group to different molecules) dramatically alters its pharmacological pathway, and appears to make the compound significantly more effective than pure synephrine. Methyl synephrine is an adrenergic amine that has unique and amplified pharmacological effects by acting, not only as a beta-3 receptor agonist, but also as an alpha-1 adrenergic agonist. This difference is significant, because pure synephrine is postulated to act as a beta-3-receptor agonist only. This means methyl synephrine works by significantly up-regulating the metabolic rate and enhancing fat metabolism and thermogenesis, while only mildly stimulating the central nervous system without adversely impacting blood pressure and heart function, unlike beta-2 receptor agonists such as ephedrine that trigger anxiety and irregular heartbeat. As a beta-3-receptor agonist, methyl synephrine up-regulates the action of epinephrine and norepinephrine (the most potent endogenous fat-burning agent around) within adipose tissue, leading to significant lipolysis. So methyl synephrine not only up-regulates fat breakdown (as a beta-3 receptor agonist), but also profoundly enhances the burning of released body fat for energy (as an alpha-1 agonist). Double punch!
As you can see, Phenadrine is no regular “kitchen-sink” formula. Rather, it represents a new standard in “double-punch” products that effectively combine intense-workout potentiating compounds with advanced lipolytic and thermogenic agents to deliver the performance you are looking for, and that we are known for. Our unique matrix of selected agents is delivered in pharmaceutical-grade purity and in potent per-dose-amounts that work every time. If you are looking for an effective double-punch product beyond the reach of competition, your search stops at Phenadrine! Advanced Lipolytic Stimulant. Intense Workout Potentiator.
References:
Armstrong WJ, Johnson P, Duhme S. The effect of commercial thermogenic weight loss supplement in body composition and energy expenditure in obese adults. J Exerc Physiol. 2001 4: 28-35, 2001.
Banderet, LE, and Lieberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull 22: 759-762, 1989.
Bell, DG, McLellan, TM. Exercise endurance 1, 3, and 6 h after caffeine ingestion in caffeine users and nonusers. J Appl Physiol. 2002 Oct;93(4):.
Bent S, Padula A, Neuhaus J. Safety and efficacy of citrus aurantium for weight loss. Am J Cardiol. 2004 Nov 15;94(10):.
Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. Ann Pharmacother. 2006 Jan;40(1):53-7. Epub 2005 Nov 29.
Camp BJ. Action of N-methyltyramine and N-methyl beta-phenylethylamine on certain biological systems. Am J Vet Res. 1970, 31(4): 755-762.
Carpéné C, Galitzky J, Fontana E, Atgié C, Lafontan M, Berlan M. Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch Pharmacol. 1999 Apr;359(4):310-21.
Cooper SJ, Dourish CT. Hypodipsia, stereotypy and hyperactivity induced by beta-phenylethylamine in the water-deprived rat. Pharmacol Biochem Behav. 1984, 20(1): 1-7.
Colker CM, Kalman DS, Torina GC, Perlis T, Street C. Effects of Citrus aurantium extract, caffeine, and St. John's Wort on body fat loss, lipid levels, and mood states in overweight, healthy adults. Curr Ther Res. 1999; 60:145-153.
Cox GR, Desbrow B, Montgomery PG, Anderson ME, Bruce CR, Macrides TA, Martin DT, Moquin A, Roberts A, Hawley JA, Burke LM. Effect of different protocols of caffeine intake on metabolism and endurance performance. J Appl Physiol. 2002 Sep;93(3):990-9.
Davis JM, Zhao Z, Stock HS, Mehl KA, Buggy J, Hand GA. Central nervous system effects of caffeine and adenosine on fatigue. Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R399-404. Epub 2002 Oct 24.
Dollins AB, Krock LP, Storm WF, Wurtman RJ, Lieberman HR. L-tyrosine ameliorates some effects of lower body negative pressure stress. Physiol Behav. 1995 Feb;57(2):223-30.
Dourish CT, Greenshaw AJ, Boulton AA. Deutrium substitution enhances the effects of b-phenylethylamine on spontaneous motor activity in the rat. Pharmacol. Biochem. Behav. 1983, 19: 471-475.
Dourish CT, Boulton AA. The effects of acute and chronic administration of beta-phenylethylamine on food intake and body weight in rats. Prog Neuropsychopharmacol. 1981, 5(4): 411-414.
Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean-Chaney S, Allison DB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev. 2006 Feb;7(1):79-88.
Grimsby J, Toth M, Chen K, Kumazawa T, Klaidman L, Adams JD, Karoum F, Gal J, Shih JC. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet. 1997, 17(2): 206-210.
Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: influences on male sexual behavior. Physiol Behav. 2004 Nitric oxidev 15;83(2):291-307
Jessen A, Buemann B, Toubro S, Skovgaard IM, Astrup A. The appetite-suppressant effect of nicotine is enhanced by caffeine. Diabetes Obes Metab. 2005 Jul;7(4):327-33.
Jiang, Z. et al Effects of icariin on hypothalamic-pituitary-adrenal axis action and cytokine levels in stressed Sprague-Dawley rats. Biol Pharm Bull. 2006 Dec;29(12):.
Jiang Z, Hu B, Wang J, Tang Q, Tan Y, Xiang J, Liu J. Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum.J Huazhong Univ Sci Technolog Med Sci.
2006;26(4):460-2.
Kruger TH, Haake P, Hartmann U, Schedlowski M, Exton MS. Orgasm-induced prolactin secretion: feedback control of sexual drive? Neurosci Biobehav Rev. 2002 Jan;26(1):31-44.
Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH, Astrup A. Effect of a 28-d treatment with L-, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002 Oct;76(4):780-8.
Lee MK, Choi YJ, Sung SH, Shin DI, Kim JW, Kim YC. Antihepatotoxic activity of icariin, a major constituent of Epimedium koreanum. Planta Med. 1995 Dec;61(6):523-6.
Liang HR, Vuorela P, Vuorela H, Hiltunen R. Isolation and immunomodulatory effect of flavonol glycosides from Epimedium hunanense. Planta Med. 1997 Aug;63(4):316-9.
Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L, Guo YL. Effects of icariin and expression of nitric oxide synthase isoforms in rats. Asian J Androl. 2005 Dec;7(4):381-8.
Liu ZQ. Icariin: a special antioxidant to protect linoleic acid against free-radical-induced peroxidation in micelles. J Phys Chem A Mol Spectrosc Kinet Environ Gen Theory. 2006 May 18;110(19):6372-8.
Nakamura M, Ishii A, Nakahara D. Characterization of b-phenylethylamine-induced monoamine release in rat nucleus accumbens: a microdialysis study. Eur. J. Pharmacol. 1998, 349: 163-169.
Neri DF, Wiegmann D, Stanny RR, Shappell SA, McCardie A, McKay DL. The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med. 1995 Apr;66(4):313-9.
Ning, H et al. Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology. 2006 Dec;68(6):1350-4.
Ning H, Xin ZC, Lin G, Banie L, Lue TF, Lin CS. Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology. 2006 Dec;68(6):1350-4.
O'Reilly R, Davis BA, Durden DA, Thorpe L, Machnee H, Boulton AA. Plasma phenylethylamine in schizophrenic patients. Biol Psychiatry. 1991, 30(2): 145-150.
Pan Y, Kong L, Xia X, Zhang W, Xia Z, Jiang F. Effect of icariin and its possible mechanism in mice. Pharmacol Biochem Behav. 2005 Dec;82(4):686-94.
Tian L, Xin ZC, Yuan YM, Fu J, Liu WJ, Wang LL. Zhonghua Yi Xue Za Zhi. 2004 Jun 2;84(11):954-7. Effects of icariin on the erectile function and expression of nitrogen oxide synthase isoforms in corpus cavernitric oxidesum of arterigenic erectile dysfunction rat model
Xu HB, Huang ZQ. Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascular Pharmacology. 2007 Jul;47(1):18-24. Epub 2007 Mar 24.
Xin ZC, Kim EK, Lin CS, Liu WJ, Tian L, Yuan YM, Fu J. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian Journal of Andrology. 2003 Mar;5(1):15-8.
Xin ZC, Kim EK, Lin CS, Liu WJ, Tian L, Yuan YM, Fu J. Asian J Androl. 2003 Mar;5(1):15-8. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.
Xu HB, Huang ZQ. Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol. 2007 Jul;47(1):18-24.
Young ME, Leighton B.(1998) Evidence for altered sensitivity of the nitric oxide/cGMP signaling cascade in insulin-resistant skeletal muscle. Biochem J. Jan 1;329 ( Pt 1):73-9
Zhang ZB, Yang QT. The testosterone mimetic properties of icariin. Asian J Androl. 2006 Sep;8(5):601-5.